Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;93(3):336-339.
doi: 10.1136/jnnp-2021-327005. Epub 2021 Aug 18.

Practice effects in genetic frontotemporal dementia and at-risk individuals: a GENFI study

Linn Öijerstedt  1   2 , Christin Andersson  3   4 , Vesna Jelic  5 , John Cornelis van Swieten  6 , Lize C Jiskoot  6 , Harro Seelaar  6 , Barbara Borroni  7 , Raquel Sanchez-Valle  8 , Fermin Moreno  9   10 , Robert Laforce Jr  11 , Matthis Synofzik  12   13 , Daniela Galimberti  14   15 , James Benedict Rowe  16 , Mario Masellis  17 , Maria Carmela Tartaglia  18 , Elizabeth Finger  19 , Rik Vandenberghe  20   21 , Alexandre de Mendonca  22 , Fabrizio Tagliavini  23 , Isabel Santana  24   25 , Simon Ducharme  26   27 , Christopher R Butler  28   29 , Alexander Gerhard  30   31 , Johannes Levin  32   33 , Adrian Danek  32 , Markus Otto  34 , Giovanni Frisoni  35 , Roberta Ghidoni  36 , Sandro Sorbi  37   38 , Jonathan Daniel Rohrer  39 , Caroline Graff  5   2 ; Genetic Frontotemporal Dementia Initiative (GENFI)
Collaborators, Affiliations

Practice effects in genetic frontotemporal dementia and at-risk individuals: a GENFI study

Linn Öijerstedt et al. J Neurol Neurosurg Psychiatry. 2022 Mar.
No abstract available

Keywords: C9ORF; frontotemporal dementia.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Trajectories of global cognitive test scores in NC and PMC by mutated gene.(A) PMC-C9 and NC (grey line, NC; yellow solid line, PMC-C9 with >5 years to expected symptom onset; yellow dashed line, PMC-C9 with <5 years to expected symptom onset). (B) PMC-GRN and NC (grey line, NC; blue solid line, PMC-GRN with >5 years to expected symptom onset; blue dashed line, PMC-GRN with <5 years to expected symptom onset). (C) PMC-MAPT and NC (grey line, NC; pink solid line, PMC-MAPT with >5 years to expected symptom onset; pink dashed line, PMC-MAPT with <5 years to expected symptom onset). All lines are fitted from the same linear mixed-effect model but plotted in A–C to simplify visualisation. Error bars represent the SEs of the means. §The difference between PMC-MAPT with >5 years to expected symptom onset and NC is no longer observed when PMC-MAPTs are compared with age-matched and family-matched controls. C9, chromosome 9 open reading frame 72; GRN, progranulin; MAPT, microtubule-associated protein tau; NC, non-carrier; PMC, presymptomatic mutation carrier.
See this image and copyright information in PMC

References

    1. Ghetti B, Buratti E, Boeve B. Frontotemporal dementias. 1st ed. Springer International Publishing, 2021: 320.
    1. Calamia M, Markon K, Tranel D. Scoring higher the second time around: meta-analyses of practice effects in neuropsychological assessment. Clin Neuropsychol 2012;26:543–70. 10.1080/13854046.2012.680913 - DOI - PubMed
    1. Jutten RJ, Grandoit E, Foldi NS, et al. Lower practice effects as a marker of cognitive performance and dementia risk: a literature review. Alzheimers Dement 2020;12:e12055. 10.1002/dad2.12055 - DOI - PMC - PubMed
    1. Duff K. Current topics in science and practice evidence-based indicators of neuropsychological change in the individual patient: relevant concepts and methods. Arch Clin Neuropsychol 2012. - PMC - PubMed
    1. Hassenstab J, Ruvolo D, Jasielec M, et al. Absence of practice effects in preclinical Alzheimer's disease. Neuropsychology 2015;29:940–8. 10.1037/neu0000208 - DOI - PMC - PubMed

Publication types

Substances